Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
Syndax Pharmaceuticals, Inc. (SNDX)
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syndax.com
Company Research
Source: GlobeNewswire
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 8:00 a.m. ET on Monday, March 3, 2025 to discuss the Company's financial results and provide a business update. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following: Conference ID: Syndax4Q24Domestic Dial-in Number: 800-590-8290International Dial-in Number: 240-690-8800Live webcast: https://www.veracast.com/webcasts/syndax/events/SNDX4Q24.cfm For those unab
Show less
Read more
Impact Snapshot
Event Time:
SNDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNDX alerts
High impacting Syndax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SNDX
News
- Syndax Pharma: Continuing Execution In AML [Seeking Alpha]Seeking Alpha
- Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025GlobeNewswire
- Syndax Pharmaceuticals (NASDAQ:SNDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $56.00 price target on the stock.MarketBeat
- Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment ContinuumGlobeNewswire
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
SNDX
Earnings
- 11/3/25 - Beat
SNDX
Sec Filings
- 12/19/25 - Form 8-K
- 12/1/25 - Form 4
- 11/3/25 - Form 10-Q
- SNDX's page on the SEC website